No open-market selling at AIM ImmunoTech Inc. in the past year, which is unusual. Instead one corporate insiders bought about $13,000 worth of AIM.
Biggest single buyer: Equels Thomas K, CEO, with roughly $5,040. Notably, at least one C-suite executive was among the buyers.
Last full quarter: net buying by insiders. Insiders bought in 3 of the last 7 full quarters. 18 investment managers listed AIM in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Equels Thomas K | CEO | Buy | 24,000 | $0.21 | $5K | SEC |
| Sep 17, 2026 | Equels Thomas K | CEO | Buy | 11,000 | $0.21 | $2K | SEC |
| Sep 16, 2026 | Equels Thomas K | CEO | Buy | 22,000 | $0.22 | $5K | SEC |
| Sep 15, 2026 | Equels Thomas K | CEO | Buy | 5,900 | $0.22 | $1K | SEC |
| Apr 23, 2025 | MITCHELL WILLIAM M | Director | Buy | 196,851 | $0.03 | $6K | SEC |
| Apr 23, 2025 | Equels Thomas K | CEO | Buy | 1,968,504 | $0.03 | $59K | SEC |
| Apr 23, 2025 | KELLNER TED D | Director | Buy | 1,968,504 | $0.03 | $59K | SEC |
| Apr 7, 2025 | Equels Thomas K | CEO | Buy | 41,000 | $0.06 | $2K | SEC |
| Apr 4, 2025 | Rodino Peter W III | COO | Buy | 500 | $0.09 | $45 | SEC |
| Mar 6, 2025 | Equels Thomas K | CEO | Buy | 50,000 | $0.13 | $6K | SEC |
| Mar 5, 2025 | Equels Thomas K | CEO | Buy | 44,000 | $0.12 | $5K | SEC |
| Mar 4, 2025 | Equels Thomas K | CEO | Buy | 83,334 | $0.12 | $10K | SEC |
| Jan 21, 2025 | Equels Thomas K | CEO | Buy | 20,000 | $0.21 | $4K | SEC |
| Dec 20, 2024 | MITCHELL WILLIAM M | Director | Sell | 4,580 | $0.19 | $870 | SEC |
| Dec 19, 2024 | Equels Thomas K | CEO | Buy | 22,727 | $0.21 | $5K | SEC |
In the last 12 months AIM ImmunoTech Inc. insiders made open-market purchases worth about $13,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AIM was filed on 2026-09-18.
18 investment managers reported holding AIM in SEC Form 13F filings for Q2 2026.
No congressional trades in AIM were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).